Myovant Sciences and HealthyWomen Launch Storytelling Initiative to Elevate Conversations About Menstrual Health
April 14 2020 - 8:30AM
Myovant Sciences (NYSE: MYOV), a healthcare company focused on
developing innovative treatments for women's health and prostate
cancer, and HealthyWomen, the nation’s leading independent,
nonprofit health information source for women, today announced a
new initiative to elevate conversations about menstrual health by
sharing diverse, personal stories of real-life impact of menstrual
stigma and symptoms. The program will be supported by The Moth, a
nonprofit organization dedicated to building empathy in the world
through the art and craft of true, personal storytelling.
As part of the initiative, HealthyWomen joins Evidation Health,
Flo Health, Myovant, and PERIOD in the Female Forward Together
coalition, which combines expertise in healthcare, research, data
science, digital health, and advocacy.
TWEET THIS: “Storytelling is a
powerful change agent and we are delighted to partner with
HealthyWomen on this important initiative to normalize
conversations about menstruation,” said Lynn Seely, M.D., chief
executive officer of Myovant. “On behalf of Female Forward
Together, we also warmly welcome HealthyWomen with its unique
expertise in health communications to the coalition.”
Results from a large-scale, digital insights survey conducted by
founding coalition members Evidation Health and Myovant showed that
menstrual stigma is pervasive. Across all demographic groups,
female and male respondents reported stigma around menstruation in
society today. Only six in 10 female respondents and half of male
respondents reported receiving adequate education about
menstruation. Furthermore, 70% of all respondents reported not
feeling comfortable talking about menstruation with a colleague,
with similar findings across audiences.
“For decades, we have made it our mission at HealthyWomen to
educate our audience about important, timely health topics, and a
significant part of our efforts has included sharing women’s
personal stories,” said Beth Battaglino, R.N., chief executive
officer of HealthyWomen. “We launched the first online site for
women’s health, and we understand the power of communication,
specifically how digital platforms continue to educate, inspire and
engage women on health topics they may feel embarrassed to speak
about. We are thrilled to join the Female Forward Together
coalition and build upon and expand information and needed
resources in women’s health.”
The initiative aims to shed light on the impact of menstrual
stigma and symptoms by sharing women’s lived experiences. Myovant
and HealthyWomen have partnered with The Moth to host a
storytelling workshop for participating women. Those interested in
sharing their stories are encouraged to visit
FemaleForwardTogether.com for more information about how to
apply.
About Myovant Sciences Myovant
Sciences aspires to be the leading healthcare company focused
on innovative treatments for women’s health and prostate cancer.
The company’s lead product candidate is relugolix, a once-daily,
oral GnRH receptor antagonist. The company has three
late-stage clinical programs for relugolix in uterine fibroids,
endometriosis, and prostate cancer. The company is also developing
MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has
completed a Phase 2a study for the treatment of female infertility
as part of assisted reproduction. Takeda Pharmaceuticals
International AG, a subsidiary of Takeda Pharmaceutical Company
Limited, the originator of relugolix, previously granted the
company a worldwide license to develop and commercialize
relugolix (excluding Japan and certain other Asian countries) and
an exclusive license to develop and commercialize MVT-602 in all
countries worldwide. Sumitovant Biopharma, Ltd., a wholly owned
subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is the majority
shareholder of Myovant. For more information, please visit the
company’s website at www.myovant.com. Follow @Myovant on
Twitter and LinkedIn.
About HealthyWomenHealthyWomen is the nation's
leading independent, nonprofit health information source for women.
Our mission is to educate, engage and inspire women, ages 35 to 64,
to make informed health choices to live and age well. We engage
with health care professionals, patient advocates, policy makers,
NGOs and corporate partners to better inform our educational
resources so that we can provide our audience with the most
reliable, medically-accurate, balanced health information. For 30+
years, millions of women have turned to HealthyWomen for answers to
their most personal health care questions.
Nothing is more important to our health than access to competent
and affordable care and the safety of our medications and health
care delivery practices. HealthyWomen works to educate women about
health policy issues in these and other areas. We recognize the
importance of clinical trials to improving women's health and we
support women's health research, particularly to account for sex
difference in research results. HealthyWomen. HealthyWomen
advocates on behalf of women to ensure that women's health is a
primary focus of policy makers and advocacy groups. Our investment
in developing science-based information and our effort to
incorporate perspectives reflected by advances in research and
technology will further our mission to provide women with relevant
and accurate health resources. For more information, please visit
www.HealthyWomen.org Follow us on Facebook, Twitter, Instagram and
LinkedIn.
Myovant Sciences Media Contact:Albert
Liao Director, Corporate CommunicationsMyovant Sciences,
Inc. media@myovant.com
HealthyWomen Media Contact: Stefanie
WilliamsonHealthyWomenstefanie@healthywomen.org
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Sep 2023 to Sep 2024